Facioscapulohumeral Muscular Dystrophy (FSHD) — Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032
Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder that primarily affects the muscles of the face, shoulder blades, and upper arms. Researchers identified two types of facioscapulohumeral muscular dystrophy (FSHD): type 1 (FSHD1) and type 2 (FSHD2) (FSHD2). The two types have identical signs and symptoms but differ due to their genetic cause. Initially, FSHD may cause weakness in the muscles of the face, shoulder girdle, and arms. Facial weakness can cause limited lip movements, making it difficult to whistle, use a straw, or pucker the lips. Affected people may develop a distinct “mask-like” facial appearance. Upper facial weakness may also result in an inability to close the eyes entirely during sleep. FSHD1 is caused by abnormal expression of the DUX4 gene, which is located on chromosome 4 in the D4Z4 region. The DNA in the D4Z4 area is typically hypermethylated and contains 11–100 repeated segments of DNA. For each pregnancy, the risk of passing the abnormal gene from the affected parent to the offspring is 50%. Males and females are both at risk.
FSHD has an estimated prevalence of 5 to 11 cases per 100,000 population in the USA. Approximately 95% of all cases are FSHD1; the remaining 5% are FSHD2.
The competitive landscape of Facioscapulohumeral Muscular Dystrophy (FSHD) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of Facioscapulohumeral Muscular Dystrophy (FSHD) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Facioscapulohumeral Muscular Dystrophy (FSHD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake, and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
S. No Asset Company Stage
1 Losmapimod Fulcrum Therapeutics Phase 3
2 ATYR1940 aTyr Pharma, Inc. Phase 2
